The surface expression of CD28 and other lymphoid co-stimulatory or co-inhibitory receptor proteins on neuroprotective PU.1low microglia highlights a new opportunity for antibody-based microglia-driven immunotherapy in AD. This evidence concerns the gene CD28 and Alzheimer disease.